VIEMED HEALTHCARE, INC. financial statements

Income statement, balance sheet and cash flow statement for the last 8 fiscal years, taken from the XBRL data VIEMED HEALTHCARE, INC. files with the SEC in its annual reports.

In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

	FY2019	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	64.5	80.3	131	117	139	183	224	270
Cost of revenue	16.7	24.3	51.2	43.7	54.2	70.2	91.1	115
Gross profit	47.8	56	80.1	73.4	84.7	113	133	155
Research and development	0	0.85	1.08	2.11	2.7	2.78	3.07	3.02
Selling, general and administrative	34.3	41.4	52.8	54.9	68.2	87.9	106	121
Operating income	10.1	8.86	26.8	11.6	8.25	14.3	17.9	22.9
Other non-operating income		-0	3.95	1.62	0.99	0.1	-0.17	0.25
Pre-tax income	9.67	8.8	26.4	12.5	8.99	14.4	16.2	21.8
Income tax	0.16	0.27	-5.17	3.38	2.77	4.15	4.76	6.39
Net income to minority interests					0	0	0.14	0.44
Net income	9.51	8.53	31.5	9.13	6.22	10.2	11.3	14.9
EBITDA	13.8	15.3	36.4	22.9	23.9	36.2	43.3	51.6
EPS, basic	0.25	0.23	0.81	0.23	0.16	0.27	0.29	0.38
EPS, diluted	0.24	0.21	0.78	0.22	0.16	0.25	0.28	0.37
Shares, basic (weighted)	37.9	37.7	38.7	39.5	38.7	38.4	38.8	38.9
Shares, diluted (weighted)	39.7	39.7	40.5	40.7	39.8	40.4	40.8	40.8

Balance sheet

	FY2019	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Cash and equivalents	10.4	13.4	31	28.4	16.9	12.8	17.5	13.5
Receivables	8.84	11.5	12.4	12.8	15.4	18.5	24.9	25.6
Inventory	2.89	1.36	2.31	2.46	3.57	4.63	4.32	5.05
Other current assets	0.95	1.56	1.51	1.73	3.85	2.45	6.11	4.13
Total current assets	23.1	27.8	47.2	47.3	39.7	38.4	52.9	48.5
Property, plant and equipment	30.6	54.8	55.1	62.8	67.7	73.6	76.3	78.8
Lease right-of-use assets					0.69	2.87	2.83	3.58
Goodwill					0	29.8	33	58.9
Intangible assets					0	0.57	0.85	1.29
Other non-current assets	0	0	0.86	0.86	1.59	0.89	0
Total assets	53.7	82.6	113	118	117	155	177	199
Accounts payable	5.88	4.7	2.1	3.24	2.65	4.18	5.32	7.33
Accrued liabilities	7.55	8.97	12.6	8.88	11.1	17.6	20.2	23.9
Deferred revenue	2.59	3.32	3.41	3.75	4.62	6.21	6.69	7.52
Short-term debt	0	1.75	1.84	1.48	0	1.07	0.41	1.09
Total current liabilities	19.6	25.9	23	17.8	18.9	32.1	37.3	41.1
Long-term debt	0	7.63	5.8	4.31	0	6	3.59	11.3
Lease liabilities					0.2	2.18	2.01	2.36
Total liabilities	21.1	38.9	30.9	23.1	19.9	41	43.8	55.6
Total debt	0	9.38	7.63	5.79	0	7.07	4	12.4
Paid-in capital	5.39	6.38	7.32	7.75	12.1	15.7	18.3	21.7
Retained earnings	27.1	34.1	65.6	73.3	69.8	79.5	89.7	103
Other comprehensive income	0	-0.16	-0.45	-0.28	0
Shareholders' equity	32.6	43.7	81.7	94.8	97.1	114	131	142
Minority interests						0	1.91	1.98
Total equity	32.6	43.7	81.7	94.8	97.1	114	133	144
Total liabilities and equity	53.7	82.6	113	118	117	155	177	199
Shares outstanding	37.5	38	39.2	39.6	38	38.5	39.1	38

Cash flow statement

	FY2019	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Net income	9.51	8.53	31.5	9.13	6.22	10.2	11.4	15.4
Depreciation and amortization	3.78	6.4	9.58	11.3	15.6	21.9	25.4	28.6
Stock-based compensation	2.7	3.89	4.88	5.15	5.2	5.85	6.29	9.13
Deferred income tax	0	0	-8.73	3.88	1.75	-1.44	-3.84	3.11
Change in receivables	-5.25	-12.5	-9.96	-7.35	-2.56	-1.06	-6.07	1.16
Change in inventory	-1.25	-0.31	-2.3	-0.21	0.3	-0.47	0.57	0.06
Cash from operations	22.4	19.1	35.1	22.5	27.7	45.2	39.1	51.9
Capital expenditures	-6.11	-13.4	-13	-19.7	-22.9	-26.1	-37.8	-40
Acquisitions					0	-28.6	-3	-26.3
Purchases of investments				0	-2	0	0
Sales and maturities of investments					0	0	0.75	0
Cash from investing	-5.3	-12.8	-8.42	-19.7	-24	-52.1	-30.7	-50.2
Debt issued	0	5
Debt repaid	0	-0.39
Stock issued	0	0.14	1.88	0.11	0.28	1.3	1.02	1.44
Share buybacks	-1.59	-1.52	0	0	-9.57	0	0	-13.2
Cash from financing	-11.8	-3.33	-9.07	-5.32	-15.3	2.83	-3.69	-5.79
Net change in cash	5.32	2.94	17.6	-2.57	-11.5	-4.08	4.7	-4.04
Free cash flow	16.3	5.7	22.1	2.75	4.85	19.1	1.32	11.9
Interest paid	0.19	0.33	0.56	0.35	0.23	0.85	0.95	0.87
Income taxes paid	0.15	0.34	3.31	1.77	-0.85	3.57	6.83	7.39

Key metrics

Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $8.91 on September 25, 2026.

Profitability

Metric	Value	How it is calculated
Gross margin	57.5%	Gross profit / revenue.
Operating margin	7.5%	Operating income / revenue.
EBITDA margin	12.8%	EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin	7.0%	Pre-tax income / revenue.
Net margin	4.8%	Net income / revenue.
FCF margin	9.7%	Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin	20.2%	Cash from operations / revenue.
Effective tax rate	29.1%	Income tax / pre-tax income, when pre-tax income is positive.
Return on equity (ROE)	10.1%	Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)	7.1%	Net income / average total assets.
Return on invested capital (ROIC)	11.5%	Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue	0.8%	Research and development expense / revenue.
SG&A / revenue	45.1%	Selling, general and administrative expense / revenue.
Stock-based pay / revenue	3.0%	Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue	10.5%	Capital expenditures / revenue.
D&A / revenue	5.3%	Depreciation and amortization / revenue.

Growth

Metric	Value	How it is calculated
Revenue growth, 1y	20.5%	Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y	24.9%	Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y	15.5%	Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y	16.7%	Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y	22.4%	Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y	14.2%	Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Operating income growth, 1y	28.2%	Operating income vs the same period a year earlier. Only from a positive base.
Operating income CAGR, 3y	40.6%	Compound annual growth of operating income over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Operating income CAGR, 5y	-3.0%	Compound annual growth of operating income over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
EBITDA growth, 1y	19.2%	EBITDA vs the same period a year earlier. Only from a positive base.
EBITDA CAGR, 3y	29.2%	Compound annual growth of ebitda over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
EBITDA CAGR, 5y	7.2%	Compound annual growth of ebitda over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Net income growth, 1y	32.6%	Net income vs the same period a year earlier. Only from a positive base.
Net income CAGR, 3y	33.9%	Compound annual growth of net income over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Net income CAGR, 5y	-13.9%	Compound annual growth of net income over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
EPS growth, 1y	32.1%	EPS vs the same period a year earlier. Only from a positive base.
EPS CAGR, 3y	32.2%	Compound annual growth of eps over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
EPS CAGR, 5y	-13.9%	Compound annual growth of eps over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Operating cash flow growth, 1y	32.8%	Operating cash flow vs the same period a year earlier. Only from a positive base.
Operating cash flow CAGR, 3y	23.2%	Compound annual growth of operating cash flow over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Operating cash flow CAGR, 5y	8.1%	Compound annual growth of operating cash flow over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Free cash flow growth, 1y	805.2%	Free cash flow vs the same period a year earlier. Only from a positive base.
Free cash flow CAGR, 3y	35.0%	Compound annual growth of free cash flow over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Free cash flow CAGR, 5y	-11.6%	Compound annual growth of free cash flow over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y	7.7%	Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y	13.4%	Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y	11.6%	Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y	12.5%	Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y	19.4%	Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y	12.1%	Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y	0.0%	Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y	0.8%	Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y	0.1%	Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.

Balance sheet health

Metric	Value	How it is calculated
Current ratio	1.13x	Current assets / current liabilities.
Quick ratio	0.90x	(Cash + short-term investments + receivables) / current liabilities.
Cash ratio	0.22x	(Cash + short-term investments) / current liabilities.
Debt / equity	0.05x	Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets	3.5%	Total debt / total assets.
Liabilities / assets	28.5%	Total liabilities / total assets.
Net debt	-$3.6M	Total debt - cash - short-term investments. Negative means more cash than debt.
Net debt / EBITDA	-0.09x	Net debt / EBITDA (twelve months), when EBITDA is positive.
Working capital	$6.1M	Current assets - current liabilities.
Goodwill and intangibles / assets	29.4%	(Goodwill + intangible assets) / total assets.
Tangible book value	$83.9M	Shareholders' equity - goodwill - intangible assets.

Efficiency

Metric	Value	How it is calculated
Asset turnover	1.48x	Revenue / average total assets.
Fixed asset turnover	3.91x	Revenue / average property, plant and equipment.
Inventory turnover	24.4x	Cost of revenue / average inventory.
Days inventory	15 days	365 x average inventory / cost of revenue.
Receivables turnover	9.36x	Revenue / average receivables.
Days sales outstanding	39 days	365 x average receivables / revenue.
Days payables	31 days	365 x average accounts payable / cost of revenue.
Cash conversion cycle	23 days	Days inventory + days sales outstanding - days payables.
FCF conversion	201.7%	Free cash flow / net income, when net income is positive.
Capex / operating cash flow	51.9%	Capital expenditures / cash from operations, when that is positive.

Per share

Metric	Value	How it is calculated
EPS, diluted	$0.35	Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share	$7.33	Revenue / diluted weighted shares.
FCF per share	$0.71	Free cash flow / diluted weighted shares.
Operating cash flow per share	$1.48	Cash from operations / diluted weighted shares.
Book value per share	$3.78	Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Tangible book per share	$2.20	Tangible book value / shares outstanding.
Cash per share	$0.28	(Cash + short-term investments) / shares outstanding.
Buybacks / FCF	62.7%	Share buybacks / free cash flow, when free cash flow is positive.

Valuation

Metric	Value	How it is calculated
Market cap	$339.4M	Share price x shares outstanding.
Enterprise value	$335.8M	Market cap + total debt - cash - short-term investments.
P/E	23.4x	Market cap / net income. Only when net income is positive.
P/S	1.13x	Market cap / revenue.
P/B	2.36x	Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book	4.04x	Market cap / tangible book value, when positive.
P/FCF	11.6x	Market cap / free cash flow. Only when free cash flow is positive.
P/OCF	5.58x	Market cap / cash from operations, when positive.
EV/Sales	1.11x	Enterprise value / revenue.
EV/EBIT	14.7x	Enterprise value / operating income, when both are positive.
EV/EBITDA	8.67x	Enterprise value / EBITDA, when both are positive.
EV/FCF	11.5x	Enterprise value / free cash flow, when both are positive.
FCF yield	8.6%	Free cash flow / market cap.
Earnings yield	4.3%	Net income / market cap (the inverse of P/E).
Shareholder yield	5.4%	(Dividends paid + share buybacks) / market cap.
PEG	0.73x	P/E / EPS growth per year over 3 years (in percent). Only when both are positive.

What was VIEMED HEALTHCARE, INC.'s revenue in fiscal 2025?

VIEMED HEALTHCARE, INC. reported revenue of $270.3M for fiscal 2025, 20.5% higher than the year before.

Was VIEMED HEALTHCARE, INC. profitable in fiscal 2025?

Yes. Net income was $14.9M, a net margin of 5.5%.

How much free cash flow did VIEMED HEALTHCARE, INC. generate in fiscal 2025?

Cash from operations of $51.9M minus capital expenditures of $40.0M left free cash flow of $11.9M.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to VIEMED HEALTHCARE, INC.